Irish biopharma firm Avadel's Q3 revenue up 55%, but net income misses estimates

Avadel Pharmaceuticals

04/11/2025 21:38

Overview

Avadel Q3 net product revenue rises 55% yr/yr to $77.5 mln

However, net income for missed analysts' expectations as costs rose sharply

Outlook

Company expects Alkermes acquisition to close in Q1 2026

Avadel progressing REVITALYZ trial for LUMRYZ, completion expected by end of 2025

Settlement with Jazz allows LUMRYZ commercialization beyond narcolepsy from March 2028

Result Drivers

LUMRYZ SALES GROWTH - Co reports 55% increase in LUMRYZ net product revenue compared to Q3 2024

PATIENT UPTAKE - Co saw 48% increase in patients using LUMRYZ as of September 30, 2025

ROYALTY COST REVERSAL - Gross profit boosted by reversal of $9.5 mln in royalty costs following settlement with Jazz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Product Revenue
$77.46 mln
Q3 EPS
Q3 Net Income
Miss
$20,000
$7.71 mln (8 Analysts)
Q3 Operating Income
Miss
$1.93 mln
$9.28 mln (8 Analysts)
Q3 Pretax Profit
Miss
$54,000
$6.56 mln (10 Analysts)
Q3 Basic EPS
Q3 Operating Expenses
$79.64 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $20.00, about 5.4% above its November 3 closing price of $18.92

The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 19 three months ago

Press Release: ID:nGNX3Pkb3g

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)